Lawrence Erik Kurzius - 31 Dec 2024 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Reporting relationship: Director
Issuer ticker: ELAN
Reported as of: 31 Dec 2024
Net transaction value: +$60,000
SEC form: 4
Accepted by SEC: 03 Jan 2025, 16:32:15 UTC
Prior SEC filing: 03 Dec 2024
Next SEC filing: 29 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Lawrence Kurzius

Key filing fact

Lawrence Erik Kurzius filed Form 4 for Elanco Animal Health Inc (ELAN) on 03 Jan 2025.

Key facts

This page summarizes Lawrence Erik Kurzius's Form 4 filing for Elanco Animal Health Inc (ELAN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jan 2025, 16:32.

Change

Previous filing in this sequence was filed on 03 Dec 2024.
Current net transaction value: +$60,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELAN transaction Derivative

Deferred Stock Units

Award

Transaction value: $60,000
Shares: +4,955
Change %: +15%
Price: $12.11
Shares after: 38,567
Date: 31 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,955
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.

Footnote F2

The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.

Footnote F3

The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $12.11 on December 31, 2024.